interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Vimseltinib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Vimseltinib, and who makes it?

Vimseltinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Vimseltinib1 dosage-form group in the Orange Book
0generic makers listed
  1. Vimseltinib appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Romvimza. No generic is listed as marketed.

20202025203020352040204501brand 2025data datePatent 9181223 listed to expire 14 March 2034Patent 12285430 listed to expire 23 December 2039Patent 12485120 listed to expire 23 December 2039Patent 12582655 listed to expire 23 December 2039Patent 11679110 listed to expire 3 February 2040Patent 11103507 listed to expire 3 February 2040Patent 12528787 listed to expire 6 December 2044Patent 12643883 listed to expire 6 December 2044Patent 12447149 listed to expire 6 December 2044Patent 12617775 listed to expire 6 December 2044Patent 12551483 listed to expire 6 December 2044Patent 12686672 listed to expire 30 April 2045Patent 12509443 listed to expire 30 April 2045Exclusivity NCE to 14 February 2030
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 February 2030Exclusivity NCE Romvimza
  • 14 March 2034Patent 9181223 drug substance
  • 23 December 2039Patent 12285430
  • 23 December 2039Patent 12485120
  • 23 December 2039Patent 12582655
  • 3 February 2040Patent 11679110
  • 3 February 2040Patent 11103507
  • 6 December 2044Patent 12528787 drug substance
  • 6 December 2044Patent 12643883 drug substance

5 more patents are listed.

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.